This study is a step forward in the search for more accurate diagnostic and prognostic tools for prostate cancer
Researchers from the Institut d’Investigació Sanitària Pere Virgili (IISPV), in collaboration with the Urology Department at the Joan XXIII University Hospital in Tarragona, have made promising progress in improving the diagnosis and monitoring of prostate cancer. The study, led by Matilde Rodríguez Chacón and Xavier Ruiz-Plazas, a specialist from the Urology Department at the same hospital, both members of the Research Group on Disease Biomarkers and Molecular Mechanisms (DIBIOMEC), was recently published in the Journal of Urology, the official journal of the American Urological Association (AUA). The research explored a panel of biomarkers found in semen samples. In the cases studied, the results were promising when combined with traditional clinical variables. Preliminary data suggest that this approach could be useful in several clinical situations, including early detection, identifying patients at higher risk of recurrence after curative treatment, and monitoring patients under active surveillance for this type of cancer.
Prostate cancer is the most common tumor among men in the Tarragona region, with around 670 new cases each year. At the national level, more than 30,000 cases are diagnosed annually, making it one of the leading causes of cancer-related death in men. This advancement, co-authored by Dr. Alves-Santiago and Dr. Altuna-Coy, both members of the DIBIOMEC group, is an important step toward personalized medicine in urology. It offers more precise tools for early detection and individualized clinical decision-making. Although more prospective studies with a larger number of patients are needed, the results so far are very promising.
Link to the scientific publication: Alves-Santiago M, Altuna-Coy A, López-Ribelles P, Arreaza-Gil V, Segarra-Tomás J, Ascaso-Til H, Garcia-Fontgivell JF, Sánchez-Martín S, Bernal-Escoté X, Ruiz-Plazas X, Chacón MR. A Semen Panel Signature Comprising sTWEAK Cytokine Levels and Expression of exomiR-221-3p and exomiR-222-3p for Assessing Prostate Cancer Prognosis, Diagnostic Utility, and Detection of Upgrading During Active Surveillance. J Urol. 2025 Aug 27:101097JU0000000000004749. doi: 10.1097/JU.0000000000004749. Epub ahead of print. PMID: 40863180.
Facebook 
Mail 
WhatsApp 
